BI1Phase III Trial of Combined Gemcitabine Plus Capecitabine Chemotherapy Versus Gemcitabine Alone in Advanced Biliary Cancer.
CO14Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon
CO15A Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC #616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil / Leucovorin Alone After Curative Resection for Patients with Stage III Colon Cancer
CO16A Randomized Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer.
CO17A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma
CO20A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux) Versus Placebo in Combination with Cetuximab (Erbitux) in Patients With K-Ras Wild Type Tumours Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma
CO21A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE).
CO23A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma
CO26A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
CO27A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for high Risk Stage III Colon Cancer in Adjuvant Setting
CO28NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial
CO29Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC III)
CO32A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation versus Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
CO9A Phase III Evaluation of High-Dose Levamisole Plus 5FU and Leucovorin as Surgical Adjuvant Therapy for High Risk Colon Cancer
GA1A Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer (TOPGEAR)
GA2INTEGRATE-A Randomized Phase II Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Esophago-Gastric Cancer (AEGC)
GA3A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
GA4A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
HE1Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
NE1NET RETREAT: A Phase II Study of 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
NE2STOPNET - A Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
PA2Phase III Adjuvant Trial In Pancreatic Cancer Comparing (1) 5FU And D-L Folinic Acid Vs (2) Gemcitabine Vs (3) No Adjuvant Treatment
PA3A Randomized Placebo Controlled Study of OSI-774 Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
PA6Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) In Patients With Resected Pancreatic Adenocarcinoma
PA7A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Inventory
Show Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| GASTRO-INTESTINAL | BI1 | 19 | 0 | 1 | 1 |
| GASTRO-INTESTINAL | CO14 | 160 | 37 | 57 | 90 |
| GASTRO-INTESTINAL | CO15 | 126 | 57 | 79 | 79 |
| GASTRO-INTESTINAL | CO16 | 59 | 2 | 0 | 2 |
| GASTRO-INTESTINAL | CO17 | 1243 | 324 | 497 | 497 |
| GASTRO-INTESTINAL | CO20 | 750 | 489 | 664 | 665 |
| GASTRO-INTESTINAL | CO21 | 1010 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO23 | 282 | 211 | 272 | 276 |
| GASTRO-INTESTINAL | CO26 | 180 | 173 | 117 | 178 |
| GASTRO-INTESTINAL | CO27 | 153 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO28 | 58 | 34 | 39 | 49 |
| GASTRO-INTESTINAL | CO29 | 223 | 164 | 9 | 168 |
| GASTRO-INTESTINAL | CO32 | Open Trial | 2 | 2 | 3 |
| GASTRO-INTESTINAL | CO9 | 208 | 0 | 2 | 2 |
| GASTRO-INTESTINAL | GA1 | 157 | 68 | 26 | 89 |
| GASTRO-INTESTINAL | GA2 | 17 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | GA3 | 16 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | GA4 | Open Trial | 3 | 0 | 3 |
| GASTRO-INTESTINAL | HE1 | 66 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | NE1 | Open Trial | 0 | 0 | 0 |
| GASTRO-INTESTINAL | NE2 | Open Trial | 0 | 1 | 1 |
| GASTRO-INTESTINAL | PA2 | 124 | 36 | 52 | 52 |
| GASTRO-INTESTINAL | PA3 | 569 | 172 | 252 | 284 |
| GASTRO-INTESTINAL | PA6 | 93 | 0 | 65 | 65 |
| GASTRO-INTESTINAL | PA7 | 191 | 24 | 46 | 56 |
(Core size is 0.6 mm)
Show
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| GASTRO-INTESTINAL | BI1 | 19 | 0 | 0 |
| GASTRO-INTESTINAL | CO14 | 160 | 0 | 0 |
| GASTRO-INTESTINAL | CO15 | 126 | 1 | 31 |
| GASTRO-INTESTINAL | CO16 | 59 | 0 | 0 |
| GASTRO-INTESTINAL | CO17 | 1243 | 6 | 216 |
| GASTRO-INTESTINAL | CO20 | 750 | 3 | 74 |
| GASTRO-INTESTINAL | CO21 | 1010 | 0 | 0 |
| GASTRO-INTESTINAL | CO23 | 282 | 3 | 176 |
| GASTRO-INTESTINAL | CO26 | 180 | 1 | 33 |
| GASTRO-INTESTINAL | CO27 | 153 | 0 | 0 |
| GASTRO-INTESTINAL | CO28 | 58 | 1 | 3 |
| GASTRO-INTESTINAL | CO29 | 223 | 0 | 0 |
| GASTRO-INTESTINAL | CO32 | Open Trial | 0 | 0 |
| GASTRO-INTESTINAL | CO9 | 208 | 0 | 0 |
| GASTRO-INTESTINAL | GA1 | 157 | 0 | 0 |
| GASTRO-INTESTINAL | GA2 | 17 | 1 | 1 |
| GASTRO-INTESTINAL | GA3 | 16 | 0 | 0 |
| GASTRO-INTESTINAL | GA4 | Open Trial | 0 | 0 |
| GASTRO-INTESTINAL | HE1 | 66 | 0 | 0 |
| GASTRO-INTESTINAL | NE1 | Open Trial | 0 | 0 |
| GASTRO-INTESTINAL | NE2 | Open Trial | 0 | 0 |
| GASTRO-INTESTINAL | PA2 | 124 | 1 | 36 |
| GASTRO-INTESTINAL | PA3 | 569 | 0 | 0 |
| GASTRO-INTESTINAL | PA6 | 93 | 1 | 47 |
| GASTRO-INTESTINAL | PA7 | 191 | 1 | 3 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| GASTRO-INTESTINAL | BI1 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO14 | 160 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO15 | 126 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO16 | 59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO17 | 1243 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO20 | 750 | 645 | 0 | 603 | 0 | 746 | 1 | 0 | 0 |
| GASTRO-INTESTINAL | CO21 | 1010 | 2 | 0 | 0 | 0 | 720 | 719 | 0 | 0 |
| GASTRO-INTESTINAL | CO23 | 282 | 281 | 0 | 0 | 0 | 282 | 282 | 0 | 0 |
| GASTRO-INTESTINAL | CO26 | 180 | 169 | 0 | 0 | 0 | 169 | 168 | 0 | 0 |
| GASTRO-INTESTINAL | CO27 | 153 | 131 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO28 | 58 | 58 | 0 | 0 | 0 | 44 | 58 | 0 | 0 |
| GASTRO-INTESTINAL | CO29 | 223 | 217 | 0 | 0 | 0 | 160 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | CO32 | Open Trial | 8 | 0 | 0 | 0 | 8 | 4 | 0 | 0 |
| GASTRO-INTESTINAL | CO9 | 208 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | GA1 | 157 | 80 | 59 | 0 | 0 | 89 | 89 | 0 | 0 |
| GASTRO-INTESTINAL | GA2 | 17 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | GA3 | 16 | 7 | 0 | 0 | 0 | 8 | 8 | 0 | 0 |
| GASTRO-INTESTINAL | GA4 | Open Trial | 6 | 0 | 0 | 0 | 6 | 6 | 0 | 0 |
| GASTRO-INTESTINAL | HE1 | 66 | 25 | 0 | 0 | 0 | 25 | 25 | 0 | 0 |
| GASTRO-INTESTINAL | NE1 | Open Trial | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | NE2 | Open Trial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | PA2 | 124 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | PA3 | 569 | 0 | 0 | 0 | 0 | 509 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | PA6 | 93 | 10 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| GASTRO-INTESTINAL | PA7 | 191 | 176 | 0 | 0 | 0 | 176 | 173 | 0 | 0 |